Healthcare stocks were flat to higher premarket Friday, with the iShares Biotechnology ETF (IBB) inactive and the State Street Health Care Select Sector SPDR ETF (XLV) up 0.8%.
Exelixis (EXEL) stock was down more than 3%after the company said the US Food and Drug Administration extended the review period for its new drug application for its metastatic colorectal cancer candidate zanzalintinib, in combination with atezolizumab, by three months.
Edwards Lifesciences (EW) maintained its 2026 financial outlook after US health regulators released an updated national coverage decision for transcatheter aortic valve replacement. Shares of Edwards Lifesciences were up 1% pre-bell.
Nutex Health (NUTX) said an unauthorized third party has published data allegedly obtained during a previously disclosed cybersecurity incident. Nutex Health shares were 0.4% higher premarket.